A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy
<br><strong>Objective: </strong>To conduct a randomized trial to test the primary hypothesis that once-daily tadalafil, administered orally for 48 weeks, lessens the decline in ambulatory ability in boys with Duchenne muscular dystrophy (DMD).</br> <br><strong>Me...
| Autori principali: | , , , , , , , , , , , , , , , |
|---|---|
| Altri autori: | |
| Natura: | Journal article |
| Lingua: | English |
| Pubblicazione: |
Wolters Kluwer Health, Inc.
2017
|